Can-Fite BioPharma (NYSE:CANF) Coverage Initiated at StockNews.com

Equities researchers at StockNews.com initiated coverage on shares of Can-Fite BioPharma (NYSE:CANF) in a report issued on Tuesday. The brokerage set a “sell” rating on the stock.

A number of other research analysts have also recently weighed in on the stock. HC Wainwright restated a “buy” rating and issued a $18.00 price objective on shares of Can-Fite BioPharma in a report on Tuesday, November 12th. D. Boral Capital restated a “buy” rating and issued a $10.00 target price on shares of Can-Fite BioPharma in a report on Tuesday, December 31st.

Can-Fite BioPharma Price Performance

Shares of CANF stock opened at $1.49 on Tuesday. The firm’s 50-day moving average is $1.54 and its two-hundred day moving average is $2.04. Can-Fite BioPharma has a 12 month low of $1.29 and a 12 month high of $4.69. The company has a market capitalization of $5.27 million, a PE ratio of -0.83 and a beta of 1.33.

Institutional Trading of Can-Fite BioPharma

An institutional investor recently raised its position in Can-Fite BioPharma stock. Rhumbline Advisers increased its position in Can-Fite BioPharma Ltd. (NYSE:CANF) by 58.6% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 26,880 shares of the company’s stock after buying an additional 9,935 shares during the period. Rhumbline Advisers owned 0.76% of Can-Fite BioPharma worth $44,000 at the end of the most recent reporting period. Institutional investors own 21.00% of the company’s stock.

About Can-Fite BioPharma

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19.